Published in Gastroenterology on July 11, 2012
Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 1.40
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.83
Barrett's esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver (2014) 0.82
Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus. World J Gastrointest Pathophysiol (2014) 0.81
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open (2015) 0.80
Barrett's oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol (2015) 0.76
Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World J Gastroenterol (2015) 0.75
Is 325 mg of prevention worth a pound of cure? Gastroenterology (2012) 0.75
The prevalence of Barrett's-esophagus-associated dysplasia in Puerto Rico. P R Health Sci J (2014) 0.75
A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. PLoS One (2017) 0.75
Barrett's oesophagus: Current controversies. World J Gastroenterol (2017) 0.75
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Adv Ther (2017) 0.75
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology (2006) 3.80
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2010) 2.24
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst (2002) 2.13
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol (2008) 2.03
Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust (2004) 1.97
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology (2001) 1.94
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer (2003) 1.75
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus (2010) 1.42
Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology (2000) 1.41
Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2 -/- C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol (2007) 1.35
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res (2006) 1.32
Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2009) 1.29
Progression of chronic hepatitis and preneoplasia in Helicobacter hepaticus-infected A/JCr mice. Toxicol Pathol (2004) 1.21
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res (2008) 1.15
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene (2006) 1.13
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology (2002) 1.09
Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2011) 1.03
Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol (2007) 1.03
Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. J Biol Chem (2010) 1.02
Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol (2000) 1.00
Regular aspirin use and esophageal cancer risk. Int J Cancer (2006) 0.92
Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol (2004) 0.91
The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Dis Esophagus (2008) 0.89
The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. Aliment Pharmacol Ther (2006) 0.85
Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci (1996) 0.81
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med (2008) 9.32
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Quality indicators for colonoscopy. Am J Gastroenterol (2006) 6.51
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos). Gastrointest Endosc (2009) 5.38
A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol (2006) 4.86
Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol (2006) 4.70
Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA (2013) 4.67
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med (2012) 4.51
A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol (2005) 4.49
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
CT screening for lung cancer: five-year prospective experience. Radiology (2005) 4.33
Quality indicators for colonoscopy. Gastrointest Endosc (2014) 4.17
A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc (2007) 4.09
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Quality indicators for colonoscopy. Gastrointest Endosc (2006) 3.83
A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol (2008) 3.54
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc (2007) 3.53
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. Gastroenterology (2008) 3.42
Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol (2003) 3.36
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet (2003) 3.26
Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology (2010) 3.24
Colorectal cancer in African Americans. Am J Gastroenterol (2005) 3.18
Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol (2007) 3.14
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol (2009) 3.04
Colorectal screening after polypectomy: a national survey study of primary care physicians. Ann Intern Med (2006) 2.98
Assessing attitudes toward laxative preparation in colorectal cancer screening and effects on future testing: potential receptivity to computed tomographic colonography. Mayo Clin Proc (2007) 2.95
Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med (2014) 2.89
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
A single-center experience of 260 consecutive patients undergoing capsule endoscopy for obscure gastrointestinal bleeding. Am J Gastroenterol (2006) 2.87
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol (2007) 2.82
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc (2007) 2.77
Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study. Gastrointest Endosc (2005) 2.77
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol (2008) 2.74
Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol (2007) 2.73
Bisphosphonates are associated with reduced risk of colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2012) 2.70
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg (2008) 2.66
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc (2011) 2.55
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med (2012) 2.47
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc (2004) 2.43
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.38
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology (2011) 2.30
Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis (2005) 2.28
Component Level Modular Design of a Solid State X-ray Image Intensifier for an M×N Array. IEEE Nucl Sci Symp Conf Rec (1997) (2010) 2.28
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
Water quality modelling of the river Yamuna (India) using QUAL2E-UNCAS. J Environ Manage (2006) 2.27
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2010) 2.24
Sphincter of Oddi manometry does not predispose to post-ERCP acute pancreatitis. Gastrointest Endosc (2004) 2.23
Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases. Gastrointest Endosc (2013) 2.22
Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World J Surg (2008) 2.22
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
Dysphagia in aging. J Clin Gastroenterol (2005) 2.17
The changing landscape of practice patterns regarding unsedated endoscopy and propofol use: a national Web survey. Gastrointest Endosc (2005) 2.16
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med (2013) 2.15
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Retention of the capsule endoscope: a single-center experience of 1000 capsule endoscopy procedures. Gastrointest Endosc (2008) 2.11
Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol (2013) 2.10
Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2012) 2.09
Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc (2007) 2.06